1-20 of 28335
Sort by
Journal Article
Inflammatory Bowel Diseases, izaf075, https://doi.org/10.1093/ibd/izaf075
Published: 17 April 2025
Journal Article
Perseus V Patel and Alka Goyal
Inflammatory Bowel Diseases, izaf049, https://doi.org/10.1093/ibd/izaf049
Published: 16 April 2025
Journal Article
Katrina S Hacker and Alana Friedlander
Inflammatory Bowel Diseases, izaf059, https://doi.org/10.1093/ibd/izaf059
Published: 16 April 2025
Journal Article
Laurie B Grossberg and others
Inflammatory Bowel Diseases, izaf016, https://doi.org/10.1093/ibd/izaf016
Published: 13 April 2025
Journal Article
Osman Cagin Buldukoglu and others
Inflammatory Bowel Diseases, izaf074, https://doi.org/10.1093/ibd/izaf074
Published: 13 April 2025
Journal Article
Miguel D Regueiro and others
Inflammatory Bowel Diseases, izaf067, https://doi.org/10.1093/ibd/izaf067
Published: 12 April 2025
Image
Published: 12 April 2025
Figure 2. IR per 1000 PYs for (A) fungal and viral infections, (B) cardiac, vascular, and circulatory disorders, (C) hepatobiliary injury/disorders, (D) malignancies, (E) eye disorders for the UC overall, UC advanced therapy, UC trial-similar, and Non-UC cohorts. *Indicates significant differences as determin
Image
Published: 12 April 2025
Figure 1. Attrition flow diagram indicating inclusion and exclusion criteria for cohort selection. a Codes could be from 2 outpatients (≥30 to ≤365 days apart) or ≥1 inpatient (≥30 to ≤365 days apart) ICD-9/10 diagnosis code for UC (K51.X). b Treatment must have occurred ±30 days from index date; convention
Image
Published: 12 April 2025
Figure 3. IR per 1000 PYs for (A) fungal and viral infections, (B) cardiac, vascular, and circulatory disorders, (C) hepatobiliary injury/disorders, (D) malignancies, (E) eye disorders for the UC overall, UC advanced therapy, UC trial-similar, and Non-UC cohorts assessed, stratified by age. *Indicates signifi
Image
Published: 12 April 2025
Figure 4. IR per 1000 PYs for (A) fungal and viral infections, (B) cardiac, vascular, and circulatory disorders, (C) hepatobiliary injury/disorders, (D) malignancies, (E) eye disorders for the UC overall, UC advanced therapy, UC trial-similar, and Non-UC cohorts assessed, stratified by baseline oral CS use. *
Image
Published: 10 April 2025
Figure 1. The abundance of Akkermansia muciniphila was negatively correlated with IL6/STAT3 pathway in Crohn’s disease (CD) patients. A, Graphical representation showing that tissue and fecal samples from 12 patients with CD and 12 healthy control. Bacteria genomic DNA of A. muciniphila was extracted from
Image
Published: 10 April 2025
Figure 2. Administration of Akkermansia muciniphila ameliorated TNBS-induced colitis in mice. A, Graphical representation showing the process of TNBS-induced chronic colitis. Mice were divided two groups as described in mentioned in Materials and Methods. B, Body weight changes were daily monitored. C, Dise
Image
Published: 10 April 2025
Figure 3. Median fluorescence intensity (MFI) of 4-1BB (A), perforin (B), MMP-1 (C), MMP-3 (D), and TNF-RII (E) in patients with active lymphocytic colitis (LC) and LC in histological remission (LC-HR), active collagenous colitis (CC) and CC in histological remission (CC-HR), active ulcerative colitis (UC) an
Image
Published: 10 April 2025
Figure 6. Performance of protein levels for multivariable classification of MC. Machine learning classification, performed by penalized logistic regression in 30 nested cross-validations, and their corresponding model variable importance scores for (A); MC active, MC-HR, and all MC vs. controls, and (B); MC a
Image
Published: 10 April 2025
Graphical Abstract Graphical Abstract
Image
Published: 10 April 2025
Graphical Abstract Graphical Abstract
Image
Published: 10 April 2025
Figure 3. Akkermansia muciniphila inhibiting IL6/STAT3 pathway in TNBS-induced colitis mice. A-B, Western blot analysis of STAT3, and p-STAT3 protein levels in CtrL, Ctrl + TNBS, and A.m + TNBS group. C-E, ELASA expressions of IL-6, STAT3, and p-STAT3 in Ctrl, Ctrl + TNBS, and A.m + TNBS group. F-H, Relative
Image
Published: 10 April 2025
Figure 1. Median fluorescence intensity (MFI) of granzyme B (A), CCL5 (B), and granzyme A (C) in patients with active lymphocytic colitis (LC) and LC in histological remission (LC-HR), active collagenous colitis (CC) and CC in histological remission (CC-HR), active ulcerative colitis (UC) and UC in remission
Image
Published: 10 April 2025
Figure 2. Median fluorescence intensity (MFI) of CCL4 (A) and CD163 (B) in patients with active lymphocytic colitis (LC) and LC in histological remission (LC-HR), active collagenous colitis (CC) and CC in histological remission (CC-HR), active ulcerative colitis (UC) and UC in remission (UC rem), non-diarrhea
Image
Published: 10 April 2025
Figure 4. Median fluorescence intensity (MFI) of APRIL (A), BAFF (B), BCMA (C), CCL20 (D), CXCL8 (E), chitinase 3-like 1 (F), pentraxin-3 (G), Fas (H), and IL-33 (I) in patients with active lymphocytic colitis (LC) and LC in histological remission (LC-HR), active collagenous colitis (CC) and CC in histologica